Sotera Health Achieves Positive Outcomes Amid Legal Victories
McIntyre Partnerships, an investment firm based in the US, reported a mixed but ultimately positive performance in the first half of 2026. While the firm experienced a flat gross return of 0% and a net return of -1% in H1, significantly underperforming the Russell 2000 Value Index's 23% return, its second quarter saw a dramatic turnaround. The portfolio surged with a 23.0% gross appreciation and 23.3% net appreciation, surpassing the index's 17.3% for the period. This robust quarterly performance was attributed to a general market upswing and several favorable developments within the firm's investments. Since its inception, the fund has maintained an impressive annual return of approximately 16% gross and 12% net, consistently outperforming the benchmark's 9% annual return. Despite the volatility introduced by its highly concentrated portfolio, with QDEL as the largest holding, McIntyre Partnerships expresses continued confidence in its investments, particularly QDEL, which is seen as a crucial growth opportunity with several promising catalysts on the horizon.
Among its notable holdings, McIntyre Partnerships specifically highlighted Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter. Sotera Health, a US-based entity, specializes in providing essential sterilization solutions, laboratory testing, and advisory services to the healthcare sector. As of August 7, 2026, the company's shares closed at $18.86, valuing its market capitalization at $5.38 billion. Sotera Health has demonstrated solid market performance, with a 5.04% return over the past month and an impressive 25.61% gain over the preceding 52 weeks. McIntyre Partnerships lauded Sotera Health's positive first-quarter results, noting the strong recovery of its Sterigenics segment, which returned to high single-digit organic growth after the inventory destocking phase in 2023 and 2024. A significant legal victory in Georgia, where a judge dismissed five lawsuits with reasoning that could lead to the rejection of 450 remaining cases, further bolstered confidence in the company's financial stability. The firm estimates that potential liabilities from these cases are likely to be below $50 million, with a worst-case scenario settlement costing around $180 million, a figure well within the context of SHC's 2026 estimated EBITDA of approximately $640 million. Additionally, a smooth CEO transition, with the former CEO moving to Executive Chairman and a new CEO appointed from Viant, has been viewed positively, ensuring leadership continuity and strategic direction.
Crucially, the investor letter also pointed out that Sotera Health's former private equity owners divested their remaining shares following the Q1 earnings. This move is anticipated to eliminate a significant overhang on SHC's stock, as the predictable quarterly block trades by these PE firms had previously constrained the share price. With this selling pressure removed, McIntyre Partnerships believes Sotera Health is now well-positioned to achieve valuations more aligned with its peers in the medical device sector. The firm projects SHC could earn approximately $1.30 per share by 2028, and a comparable valuation to similar growth-oriented medical device companies, typically trading at around 25 times price-to-earnings, would suggest a potential doubling of SHC's current share price.
Sotera Health Company's strategic advancements and favorable market conditions present a compelling narrative of resilience and potential. The company's ability to navigate legal challenges and maintain robust operational growth underscores a strong foundation for future value creation. With the removal of prior market pressures, Sotera Health is poised for an upward trajectory, reflecting the dynamic nature of innovation and sound management in the healthcare industry.
